Diabetes is a growing disease and an enormous global burden that is projected to affect more than 592 million people by 2035. AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes.
Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research program. AstraZeneca is committed to advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes.
Type 2 diabetes is a metabolic disorder characterised by chronically high levels of glucose in the blood. Find out more about the condition and its prevalence.
Bydureon (exenatide extended-release injectable suspension) is indicated in adults 18 years old for patients with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.
Forxiga (dapagliflozin) is indicated in adults aged 18 years and older with type 2 diabetes to improve glycaemic control.
Onglyza (saxagliptin) is indicated in adults with type 2 diabetes mellitus to improve glycaemic control in combination with diet and exercise.
QTERN (saxagliptin/ dapagliflozin), fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus.
GB-9784 - November 2017